$FPRX News
Last published 4y ago
- 4y agoFACTFPRXPDLIApexigen Announces Appointment of Francis Sarena as Chief Operating OfficerGlobeNewswireSAN CARLOS, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Apexigen, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing a new generation of antibody therapeutics for oncology, today announced the appointment of Francis Sa
- 5y agoAMGNFPRXAmgen Successfully Completes Acquisition Of Five Prime TherapeuticsPR NewswireAmgen (NASDAQ:AMGN) today announced that it has successfully completed its previously announced tender offer to purchase all outstanding shares of...
- 5y agoFPRXFive Prime Cancels Fourth Quarter and Full-Year 2020 Financial Results Conference CallBusiness WireSOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Five Prime Therapeutics, Inc. (NASDAQ: FPRX) announced today that it has canceled its fourth quarter and full year 2020 earnings conference call, which was previously scheduled for Wednesday, March 10, 2021 at 1:30 p.m. PT / 4:30 p.m. ET.
- 5y agoFPRXSVBISOACCAPMoore Kuehn Encourages FPRX, SVBI, SOAC, and CAP Investors to Contact Law FirmPR NewswireMoore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims...
- 5y agoGILDFPRXAMGNAmgen Bulks Up Cancer Pipeline With $1.9 Billion Five Prime DealBloombergAmgen Inc. said that it had agreed to buy Five Prime Therapeutics Inc. for $1.9 billion in cash, in a deal that will add new cancer therapies to the pharmaceutical giant’s pipeline.
- 5y agoAMGNFPRXAmgen To Acquire Five Prime Therapeutics For $1.9 Billion in CashPR NewswireAmgen (NASDAQ: AMGN) and Five Prime Therapeutics (NASDAQ: FPRX), a clinical-stage biotechnology company focused on developing immuno-oncology and...
- 5y agoAMGNFPRXAmgen to Acquire Five Prime Therapeutics for $1.9 Billion in CashBusiness WireTHOUSAND OAKS, Calif. & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Amgen (NASDAQ: AMGN) and Five Prime Therapeutics (NASDAQ: FPRX), a clinical-stage biotechnology company focused on developing immuno-oncology and targeted cancer therapies, today announced an agreement under which Amgen will acquire Five Prime Therapeutics for $38.00 per share in cash, representing an equity value of approximate ...
- 5y agoFPRXFive Prime Therapeutics Announces Timing of Its Fourth Quarter 2020 and Full Year Results Conference CallBusiness WireSOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Five Prime Therapeutics, Inc. (NASDAQ: FPRX), will report its fourth quarter and full year 2020 operational and financial results on Wednesday, March 10, 2021 after the U.S. financial markets close. Five Prime will also host a conference call and live audio webcast that same day at 4:30 p.m. (ET) / 1:30 p.m. (PT) to provide a general business update an ...
- 5y agoFPRXFive Prime Therapeutics to Participate in the Cowen 41st Annual Health Care ConferenceBusiness WireSOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Five Prime Therapeutics, Inc. (NASDAQ: FPRX) today announced that Tom Civik, President and Chief Executive Officer, and Helen Collins, M.D., Executive Vice President and Chief Medical Officer are scheduled to participate in a fireside chat at the Cowen 41st Annual Health Care Conference on Thursday, March 4, 2021 at 10:30 a.m. ET / 7:30 a.m. PT.
- 5y agoFPRXFive Prime Therapeutics to Participate in the SVB Leerink 10th Annual Global Healthcare ConferenceBusiness WireSOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Five Prime Therapeutics, Inc. (NASDAQ: FPRX) today announced that Tom Civik, President and Chief Executive Officer, and Helen Collins, M.D., Executive Vice President and Chief Medical Officer are scheduled to participate in a fireside chat at the virtual SVB Leerink 10th Annual Global Healthcare Conference on Thursday, February 25, 2021 at 10:00 a.m. E ...
- 5y agoFPRXFive Prime Therapeutics to Participate in Guggenheim Healthcare Talks 2021: Oncology DayBusiness WireSOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Five Prime Therapeutics, Inc. (NASDAQ: FPRX) today announced that Tom Civik, President and Chief Executive Officer, and Helen Collins, M.D., Executive Vice President and Chief Medical Officer, are scheduled to participate in a fireside chat at the virtual Guggenheim Healthcare Talks: Oncology Day on Friday, February 12, 2021 at 1:00 p.m. ET/10:00 a.m. ...
- 5y agoFPRXPhase 2 FIGHT Trial Results Presented at ASCO GI Validate Importance of FGFR2b Overexpression and Reinforce Potential of Bemarituzumab Plus Chemotherapy as a Frontline Targeted Treatment for FGFR2b+ Gastric and GEJ CancersBusiness WireSOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Five Prime Therapeutics, Inc. (NASDAQ: FPRX) today announced clinical results from the global, randomized, double-blind placebo-controlled Phase 2 FIGHT trial evaluating first-in-class targeted therapy bemarituzumab in advanced gastric or gastroesophageal junction (GEJ) cancer. Trial results were presented in a late-breaking oral presentation today by ...
- 5y agoFPRXFive Prime to Present Phase 2 FIGHT Trial Results of Bemarituzumab at American Society of Clinical Oncology (ASCO) Gastrointestinal (GI) Cancers Virtual Annual SymposiumBusiness WireSOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Five Prime Therapeutics, Inc. (NASDAQ: FPRX), a clinical-stage biotechnology company focused on developing immune modulators and precision therapies for solid tumor cancers, today announced that detailed results from the global, randomized, double-blind placebo-controlled Phase 2 FIGHT trial evaluating bemarituzumab plus mFOLFOX6 chemotherapy in patien ...
- 5y agoFPRXFive Prime Announces Closing of Upsized Public Offering of Common StockBusiness WireSOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Five Prime Therapeutics, Inc. (Nasdaq: FPRX) announced today the closing of its upsized underwritten public offering of 8,280,000 shares of its common stock, which includes 1,080,000 shares sold upon the underwriters’ full exercise of their option to purchase additional shares, resulting in aggregate gross proceeds of approximately $173.9 million, befo ...
- 5y agoFPRXFive Prime Announces Pricing of Upsized Public Offering of Common StockBusiness WireSOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Five Prime Therapeutics, Inc. (Nasdaq: FPRX), announced today the pricing of an underwritten public offering of 7,200,000 shares of its common stock at a price to the public of $21.00 per share. The size of the offering was upsized from 5,000,000 shares to 7,200,000 shares. Five Prime estimates that the net proceeds from the sale of the shares will be ...
- 6y agoFPRXFive Prime Presents First Preclinical Data on Anti-CCR8 Antibody FPA157Business WireSOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Five Prime Therapeutics, Inc. (NASDAQ: FPRX) today presented the first preclinical data from its anti-CCR8 FPA157 program at The Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting & Pre-Conference Programs (SITC 2020).
- 6y agoFPRXFive Prime Announces Proposed Public Offering of Common StockBusiness WireSOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Five Prime Therapeutics, Inc. (Nasdaq: FPRX), a clinical-stage biotechnology company focused on developing immune modulators and precision therapies for solid tumor cancers, announced today that it plans to offer and sell, subject to market and other conditions, 5,000,000 shares of its common stock in an underwritten public offering. In connection with ...
- 6y agoWEIWFCFPRXSmall-Cap Biotech Surges Almost 350% on Cancer-Drug Trial DataBloombergSmall-cap drug developer Five Prime Therapeutics Inc. is on track to post one of this year’s biggest daily stock moves after reporting promising data from a mid-stage cancer study.
- 6y agoZLABFPRXZai Lab Partner Five Prime Therapeutics Announces Bemarituzumab Plus Chemotherapy Demonstrates Significant Progression-Free and Overall Survival Benefit Compared to Placebo Plus Chemotherapy in Front-Line Advanced Gastric or Gastroesophageal Junction CancerGlobeNewswireAll three efficacy endpoints in the global Phase 2 FIGHT trial met pre-specified statistical significance• Median progression-free survival (PFS) improved from 7.4 months in the placebo arm to 9.5...
- 6y agoFPRXFive Prime Announces Bemarituzumab Plus Chemotherapy Demonstrates Significant Progression-Free and Overall Survival Benefit Compared to Placebo Plus Chemotherapy in Front-Line Advanced Gastric and Gastroesophageal Junction CancerBusiness WireSOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Five Prime Therapeutics, Inc. (NASDAQ: FPRX) ), a clinical-stage biotechnology company focused on developing immune modulators and precision therapies for solid tumor cancers, today announced positive topline results from the global, randomized, double-blind placebo-controlled Phase 2 FIGHT trial. The trial compared mFOLFOX6 chemotherapy in combination ...
- 6y agoFPRXFive Prime Therapeutics, Inc. (FPRX) CEO Tom Civik On Q3 2020 Results - Quick Version Earnings Call TranscriptEarnings Call Transcripts
- 6y agoFPRXFive Prime Therapeutics Reports Third Quarter 2020 ResultsBusiness WireSOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Five Prime Therapeutics, Inc. (NASDAQ: FPRX), a clinical-stage biotechnology company focused on developing immune modulators and precision therapies for solid tumor cancers, today announced results for the third quarter of 2020 in addition to providing an update on the company’s recent activities.
- 6y agoFPRXFive Prime to Present First Preclinical Data of Anti-CCR8 Antibody FPA157 at Society for Immunotherapy of Cancer Virtual Annual MeetingBusiness WireSOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Five Prime Therapeutics, Inc. (NASDAQ: FPRX), a clinical-stage biotechnology company focused on developing immune modulators and precision therapies for solid tumor cancers, today announced the upcoming virtual poster presentation of the first preclinical data from its anti-CCR8 antibody, FPA157 program, at the Society for Immunotherapy of Cancer (SITC ...
- 6y agoFPRXFive Prime Therapeutics Announces Timing of Its Third Quarter 2020 Results Conference CallBusiness WireSOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Five Prime Therapeutics, Inc. (NASDAQ: FPRX), a clinical-stage biotechnology company focused on developing immune modulators and precision therapies for solid tumor cancers, will report its third quarter 2020 operational and financial results on Tuesday, November 3, 2020 after the U.S. financial markets close. Five Prime will also host a conference cal ...
- 6y agoFPRXPipeline Therapeutics Appoints Lori Lyons-Williams to its Board of DirectorsBusiness WireSAN DIEGO--(BUSINESS WIRE)--Pipeline Therapeutics, a biopharmaceutical company focused on the development and commercialization of first-in-class small molecules for neuroregeneration, today announced the appointment of Lori Lyons-Williams to the company’s Board of Directors. Ms. Lyons-Williams brings more than 20 years of executive and operational experience to Pipeline.
- 6y agoFPRXFive Prime Therapeutics to Participate in the 2020 Wells Fargo Virtual Healthcare ConferenceBusiness WireSOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Five Prime Therapeutics, Inc. (NASDAQ: FPRX), a clinical-stage biotechnology company focused on developing immune modulators and precision therapies for solid tumor cancers, today announced that Tom Civik, Chief Executive Officer of Five Prime Therapeutics, and Helen Collins, M.D., Executive Vice President and Chief Medical Officer of Five Prime Therap ...
- 6y agoFPRXFive Prime Therapeutics, Inc. (FPRX) CEO Tom Civik on Q2 2020 Results - Earnings Call TranscriptEarnings Call Transcripts
- 6y agoFPRXFive Prime Therapeutics Reports Second Quarter 2020 ResultsBusiness WireSOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Five Prime Therapeutics, Inc. (NASDAQ: FPRX), a clinical-stage biotechnology company focused on developing immune modulators and precision therapies for solid tumor cancers, today announced results for the second quarter of 2020 in addition to providing an update on the company’s recent activities.
- 6y agoFPRXFive Prime Therapeutics to Present at the 2020 Wedbush PacGrow Healthcare Virtual ConferenceBusiness WireSOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Five Prime Therapeutics, Inc. (NASDAQ: FPRX), a clinical-stage biotechnology company focused on developing immune modulators and precision therapies for solid tumor cancers, today announced that Tom Civik, Chief Executive Officer of Five Prime Therapeutics, and Helen Collins, M.D., Executive Vice President and Chief Medical Officer of Five Prime Therap ...
- 6y agoFPRXFive Prime Therapeutics Announces Timing of Its Second Quarter 2020 Results Conference CallBusiness WireSOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Five Prime Therapeutics, Inc. (NASDAQ: FPRX), a clinical-stage biotechnology company focused on developing immune modulators and precision therapies for solid tumor cancers, will report its second quarter 2020 operational and financial results on Thursday, August 6, 2020 after the U.S. financial markets close. Five Prime will also host a conference cal ...
- 6y agoFPRXFive Prime Therapeutics, Inc. (FPRX) CEO Thomas Civik on Q1 2020 Results - Earnings Call TranscriptEarnings Call Transcripts
- 6y agoFPRXFive Prime Therapeutics Announces Timing of Its First Quarter 2020 Results Conference CallBusiness WireSOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Five Prime Therapeutics, Inc. (NASDAQ: FPRX), a clinical-stage biotechnology company focused on developing immune modulators and precision therapies for solid tumor cancers, will report its first quarter 2020 operational and financial results on Thursday, May 7, 2020 after the U.S. financial markets close. Five Prime will also host a conference call an ...
- 6y agoFPRXFive Prime Therapeutics Changes 2020 Annual Meeting to Virtual FormatBusiness WireSOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Five Prime Therapeutics, Inc. (NASDAQ: FPRX), a clinical-stage biotechnology company focused on developing immune modulators and precision therapies for solid tumor cancers, today announced that its 2020 Annual Meeting of Stockholders will take place virtually and will be available as a live audio webcast. The company is making this change to comply wi ...
- 6y agoFPRXFive Prime Therapeutics Announces Publication of the Phase 1 Bemarituzumab Study in the Journal of Clinical OncologyBusiness WireSOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Five Prime Therapeutics, Inc. (NASDAQ: FPRX), a clinical-stage biotechnology company focused on developing immune modulators and precision therapies for solid tumor cancers, today announced the publication of results from the phase 1 escalation and expansion study of bemarituzumab in patients with advanced solid tumors and FGFR2b-selected gastroesophag ...
- 6y agoFPRXFive Prime Therapeutics Reports Fourth Quarter and Full Year 2019 ResultsBusiness WireSOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Five Prime Therapeutics, Inc. (NASDAQ: FPRX), a clinical-stage biotechnology company focused on developing immune modulators and precision therapies for solid tumor cancers, today announced results for the fourth quarter and year ended December 31, 2019, in addition to providing an update on the company’s recent activities.
- 6y agoFPRXFive Prime Therapeutics to Present at Upcoming Healthcare ConferenceBusiness WireSOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Five Prime Therapeutics, Inc. (NASDAQ: FPRX), a clinical-stage biotechnology company focused on developing immune modulators and precision therapies for solid tumor cancers, today announced that Helen Collins, M.D., Executive Vice President and Chief Medical Officer, is scheduled to present at the following investor conference:
- 6y agoFPRXFive Prime Therapeutics Licenses Antibodies to Seattle Genetics for Use in Novel Antibody Drug Conjugate (ADC) ProgramsBusiness WireSOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Five Prime Therapeutics, Inc. (NASDAQ: FPRX), a clinical-stage biotechnology company focused on developing immune modulators and precision therapies for solid tumor cancers, today announced a global license agreement with Seattle Genetics, Inc. to develop and commercialize novel antibody-drug conjugate (ADC) therapies using monoclonal antibodies develo ...
- 6y agoFPRXFive Prime Therapeutics Provides Update on Phase 2 Trial of Cabiralizumab Combined with Opdivo® in Pancreatic CancerBusiness WireSOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Five Prime Therapeutics, Inc. (NASDAQ: FPRX), a clinical-stage biotechnology company focused on developing immune modulators and precision therapies for solid tumor cancers, today announced that Bristol-Myers Squibb informed the company that the randomized Phase 2 trial testing the combination of cabiralizumab with Opdivo® (nivolumab) with and without ...
- 6y agoFPRXFive Prime Therapeutics Announces Timing of Its Fourth Quarter and Full Year 2019 Results Conference CallBusiness WireSOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Five Prime Therapeutics, Inc. (NASDAQ: FPRX), a clinical-stage biotechnology company focused on developing immune modulators and precision therapies for solid tumor cancers, will report its fourth quarter and full year 2019 operational and financial results on Thursday, February 27, 2020 after the U.S. financial markets close. Five Prime will also host ...
- 6y agoFPRXFive Prime Therapeutics to Participate in the 38th Annual J.P. Morgan Healthcare ConferenceBusiness WireSOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Five Prime Therapeutics, Inc. (NASDAQ: FPRX), a clinical-stage biotechnology company focused on developing immune modulators and precision therapies for solid tumor cancers, will participate in the 38th Annual J.P. Morgan Healthcare Conference on Thursday, January 16, 2020. William Ringo, who is Five Prime’s Chairman and interim Chief Executive Officer ...
- 6y agoFPRXFive Prime Therapeutics Announces Resignation of Dr. Lewis T. “Rusty” Williams From Board of DirectorsBusiness WireSOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Five Prime Therapeutics, Inc. (NASDAQ: FPRX), a clinical-stage biotechnology company focused on developing immune modulators and precision therapies for solid tumor cancers, today announced that the company’s founder, Lewis T. "Rusty" Williams, M.D., Ph.D., has resigned as a member of the Five Prime Board of Directors to focus on his role as Chief Exec ...
- 7y agoFPRXFive Prime Therapeutics Presents Initial Safety Data from the Phase 1 Trial of FPT155 at the Society for Immunotherapy of Cancer Annual MeetingBusiness WireSOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Five Prime Therapeutics, Inc. (NASDAQ: FPRX), a clinical-stage biotechnology company focused on developing immune modulators and precision therapies for solid tumor cancers, today presented initial safety data from the Phase 1 clinical trial of FPT155 in patients with advanced solid tumors in a poster presentation at the Society for Immunotherapy of Ca ...
- 7y agoFPRXFive Prime Therapeutics, Inc. (FPRX) CEO William Ringo on Q3 2019 Results - Earnings Call TranscriptEarnings Call Transcripts
- 7y agoFPRXFive Prime Therapeutics Reports Third Quarter 2019 ResultsBusiness WireSOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Five Prime Therapeutics, Inc. (NASDAQ: FPRX), a clinical-stage biotechnology company focused on developing immune modulators and precision therapies for solid tumor cancers, today announced its results for the third quarter and provided an update on the company’s recent activities.
- 7y agoFPRXFive Prime Therapeutics to Announce Third Quarter 2019 Financial Results and Host Conference CallBusiness WireSOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Five Prime Therapeutics, Inc. (NASDAQ: FPRX), a clinical-stage biotechnology company focused on developing immune modulators and precision therapies for solid tumor cancers, will report its third quarter 2019 financial results on Wednesday, November 6, 2019 after the U.S. financial markets close. Five Prime will also host a conference call and live aud ...
- 7y agoFPRXFive Prime Announces RestructuringBusiness WireSOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Five Prime Therapeutics, Inc. (NASDAQ: FPRX), a clinical-stage biotechnology company focused on discovering and developing immune modulators and precision therapies for solid tumor cancers, announced today a corporate restructuring to extend the company’s cash runway without impacting or delaying the data timelines of its clinical programs. The company ...
- 7y agoFPRXFive Prime Therapeutics Presents Updated Data From the Phase 1a/1b Trial of FPA150 at the European Society for Medical Oncology 2019 CongressBusiness WireSOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Five Prime Therapeutics, Inc. (NASDAQ: FPRX), a clinical-stage biotechnology company focused on discovering and developing immune modulators and precision therapies for solid tumor cancers, today presented updated data from the Phase 1a/1b clinical trial of FPA150 in patients with advanced solid tumors in a poster presentation at the European Society f ...
- 7y agoFPRXFive Prime Therapeutics Announces Management TransitionBusiness WireSOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Five Prime Therapeutics, Inc. (NASDAQ: FPRX), a clinical-stage biotechnology company focused on discovering and developing immune modulators and precision therapies for solid tumor cancers, announced today that its Board of Directors has appointed William “Bill” Ringo as Interim Chief Executive Officer, effective immediately. Mr. Ringo will succeed Chi ...
- 7y agoFPRXFive Prime Therapeutics to Present at Upcoming Healthcare ConferenceBusiness WireSOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Five Prime Therapeutics, Inc. (NASDAQ: FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics today announced that Aron Knickerbocker, Chief Executive Officer, is scheduled to present at the following healthcare conference:
- 7y agoFPRXFive Prime Therapeutics Reports Second Quarter 2019 ResultsBusiness WireSOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Five Prime Therapeutics, Inc. (NASDAQ: FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, today announced its results for the second quarter and provided an update on the company’s recent activities.